Feb 02, 2023
- Corporate
Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Toshiya Sasai |
| Head of Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0554 |
Chugai Pharmaceutical Co., Ltd. hereby announces that there is a difference regarding the individual financial results (Japanese standard) for the year ended December 2022 (Jan. 1, 2022 – Dec. 31, 2022) as compared to the actual results for the previous year (Jan. 1, 2021 – Dec. 31, 2021).
1. Difference between the actual results for the year ended December 2022 and the actual results for the previous year
| Revenues | Operating Income | Ordinary Income | Net Income | Earnings per Share | |
|---|---|---|---|---|---|
| Actual results for the previous year (A) (Jan. 1, 2021 – Dec. 31, 2021) |
(millions of yen) 993,350 |
(millions of yen) 410,313 |
(millions of yen) 414,116 |
(millions of yen) 294,713 |
(Yen Sen) 179.25 |
| Actual results for this year (B) (Jan. 1, 2022 – Dec. 31, 2022) |
(millions of yen) 1,250,901 |
(millions of yen) 517,816 |
(millions of yen) 525,010 |
(millions of yen) 366,728 |
(Yen Sen) 222.96 |
| Change (B-A) | (millions of yen) 257,551 |
(millions of yen) 107,503 |
(millions of yen) 110,894 |
(millions of yen) 72,015 |
- |
| Change (%) | 25.9 | 26.2 | 26.8 | 24.4 | - |
2. Reasons for the difference occurring
The difference occurred mainly due to the strong performance of new products and mainstay products in the domestic market, increases in exports to Roche, as well as income related to the settlement agreement with Alexion Pharmaceuticals, Inc.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
